Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for TScan Therapeutics (TCRX) over the last 4 years, with Q3 2025 value amounting to $1.3 million.

  • TScan Therapeutics' Other Non Operating Income fell 5093.24% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 2565.23%. This contributed to the annual value of $7.3 million for FY2024, which is 7268.87% up from last year.
  • TScan Therapeutics' Other Non Operating Income amounted to $1.3 million in Q3 2025, which was down 5093.24% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Other Non Operating Income registered a high of $2.7 million during Q3 2024, and its lowest value of -$74000.0 during Q4 2022.
  • Its 4-year average for Other Non Operating Income is $1.1 million, with a median of $1.2 million in 2024.
  • As far as peak fluctuations go, TScan Therapeutics' Other Non Operating Income soared by 247142.86% in 2023, and later tumbled by 5093.24% in 2025.
  • Quarter analysis of 4 years shows TScan Therapeutics' Other Non Operating Income stood at -$74000.0 in 2022, then surged by 2456.76% to $1.7 million in 2023, then tumbled by 48.22% to $903000.0 in 2024, then surged by 48.62% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.7 million for Q2 2025, and $2.1 million during Q1 2025.